MustGrow Closes Non-Brokered LIFE Offering of Approximately $2.1 Million, Repricing of Warrants, and Shares for Debt Settlement
Saskatoon, Saskatchewan--(Newsfile Corp. - August 29, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce: (i) the closing of its previously annoucned non-brokered private placement of 3,059,731 units of the Company (each, a "Unit") at a price of $0.70 per Unit for gross proceeds of approximately $2,141,812 (the "LIFE Offering"); (ii) the repricing of outstanding share purchase warrant
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2025-08-29 7:00 AM EDT | MustGrow Biologics Corp.
PreveCeutical Announces Rescheduled Date for Annual General and Special Meeting and Director Resignation
Vancouver, British Columbia--(Newsfile Corp. - August 28, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) (the "Company" or "PreveCeutical") announces that, further to its News Release of June 25, 2025, July 8, 2025 and August 5, 2025, it has rescheduled its annual general and special meeting (the "Meeting") from September 29, 2025 to October 10, 2025 due to the necessity to comply with the various requirements in connection with the proposed plan of
Biotechnology, Pharmaceuticals, Health
2025-08-28 6:00 PM EDT | PreveCeutical Medical Inc.
Hemostemix Announces Financing Plans for VesCell(TM) Treatment
Calgary, Alberta--(Newsfile Corp. - August 28, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, under Florida's SB 1768, announces it has organized patient financi
Biotechnology, Pharmaceuticals, Health
2025-08-28 2:52 PM EDT | Hemostemix Inc.
Nextleaf Reports Third Quarter FY25 Results Including Fourth Consecutive Profitable Quarter
Vancouver, British Columbia--(Newsfile Corp. - August 28, 2025) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), an innovation-driven life science company and licensed cannabis processor, is pleased to announce its financial results for the third quarter of fiscal year 2025, ended June 30, 2025. The Company reported gross revenue of $3,769,797, net revenue of $2,912,572 and gross profit of $1,107,593. This marks the Company's four
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2025-08-28 9:00 AM EDT | Nextleaf Solutions Ltd.
Therma Bright Proposes to Amend Certain Warrants
Toronto, Ontario--(Newsfile Corp. - August 28, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma Bright" or the "Company") announces that subject to the approval of the TSX Venture Exchange (the "TSXV"), the Company intends to amend the exercise price of an aggregate of 6,250,000 outstanding post-consolidation common share purchase warrants of the Company (the "Warrants") that were issued as part of the Company's private placement ("Pri
Technology, Biotechnology, Health
2025-08-28 7:00 AM EDT | Therma Bright Inc.
MustGrow Announces Record Q2-2025 Results: $2.8 Million Revenue and 20.9% Gross Profit Margin for the Quarter
Saskatoon, Saskatchewan--(Newsfile Corp. - August 27, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF)
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2025-08-27 7:00 PM EDT | MustGrow Biologics Corp.
OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025
New York, New York--(Newsfile Corp. - August 27, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will provide stakeholders with a detailed update regarding the Company’s highly constructive August 27, 2025 End of Phase 2 Meeting with the US Food & Drug Administration ("FDA") discussing the regulatory path forward towards approva
2025-08-27 4:01 PM EDT | OS Therapies
PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx(TM)), Aligned with FDA's CNPV National Priority Initiative
Toronto, Ontario--(Newsfile Corp. - August 27, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, today announced the advancement of its ketamine transdermal patch as a next-generation, non-opioid pain relief solution, building on the recent FDA approval of its IV ketamine product (KETARx™). "With KETARx™ now FDA-approved, our next
Biotechnology, Pharmaceuticals
2025-08-27 8:00 AM EDT | PharmaTher Holdings Ltd.
Theralase(R) Releases 2Q2025 Financial Statements
Toronto, Ontario--(Newsfile Corp. - August 26, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company's unaudited condensed consolidated interim 2Q2025 financial statements ("Financial Statements"). Theralase® will be host
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-08-26 4:30 PM EDT | Theralase Technologies Inc.
Hemostemix's Boots on the Ground in Florida
Calgary, Alberta--(Newsfile Corp. - August 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, under Florida's SB 1768, announces the launch of its face-to-face s
Biotechnology, Pharmaceuticals, Health
2025-08-26 9:12 AM EDT | Hemostemix Inc.
Envoy Medical Extinguishes over $32 Million in Debt, Strengthening Balance Sheet; Announces Retirement of Glen A. Taylor from Board
White Bear Lake, Minnesota--(Newsfile Corp. - August 26, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced it has satisfied and extinguished the outstanding term loans from GAT Funding, LLC, which totaled $32 million in outstanding principal and accrued interest, in exchange for a payment of $100,000 in cash. GAT Funding is owned by Glen A. Taylor, wh
Biotechnology, Healthcare and Hospitals
2025-08-26 8:00 AM EDT | Envoy Medical, Inc.
Izotropic Announces Non-Brokered Private Placement & Extends Warrants
British Columbia and Sacramento, California--(Newsfile Corp. - August 26, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it intends to complete a small non-brokered private placement financing (the "Offering") o
2025-08-26 8:00 AM EDT | Izotropic Corporation
NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders
Announced unprecedented Phase 1b/2a topline results in chronic spinal cord injury NVG-291 is the first pharmacologic candidate to demonstrate statistically significant improvement in corticospinal connectivity with clinically meaningful functional gains Ongoing comprehensive analysis of NVG-291's efficacy profile will support upcoming regulatory discussions, including seeking alignment with FDA on potential expedited approv
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-26 7:30 AM EDT | NervGen Pharma Corp.
OS Therapies Terminates Equity Line of Credit
New York, New York--(Newsfile Corp. - August 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it terminated its Equity Purchase Agreement (the "ELOC") with Square Gate Capital Master Fund, LLC — Series 3, effective August 26, 2025. "The recent success of our warrant exercise inducement and exchange offering provided the Company
2025-08-25 9:51 PM EDT | OS Therapies
Sona Provides Update on First-In-Human Clinical Trial
Halifax, Nova Scotia--(Newsfile Corp. - August 25, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, is pleased to provide an update on the first-in-human early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment with late-stage melanoma patients. The treatment and follow-up assessments o
2025-08-25 9:14 AM EDT | Sona Nanotech Inc.
Defence Therapeutics Announces Debenture Units Financing
Montreal, Quebec--(Newsfile Corp. - August 22, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce a non-brokered private placement of debenture units (the "Units") at a price of $1,000 per Unit for aggregate gross proceeds of up to $1,200,000 (the "Offering"). Each Unit will consist of (i) one $1,000 principal amount of
Biotechnology, Pharmaceuticals, Health
2025-08-22 8:30 PM EDT | Defence Therapeutics Inc.
Restart Life Sciences Provides Corporate Update on Strategy and Growth Initiatives
Vancouver, British Columbia--(Newsfile Corp. - August 21, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") today announced that it has elected to cancel its previously planned LIFE financing, originally announced on July 8, 2025. The decision follows a review of evolving priorities and market opportunities. While the LIFE structure remains a useful tool, policy restrictions limit flexibility. With new opportunities under dis
Technology, Biotechnology, Health
2025-08-21 4:00 PM EDT | Restart Life Sciences Corp.
iSpecimen Announces Completion of Milestone 1 in Digital Transformation Journey with Salestack Platform
Woburn, Massachusetts--(Newsfile Corp. - August 21, 2025) - iSpecimen Inc. (NASDAQ: ISPC), an online marketplace for human biospecimens, today announced the successful completion of Milestone 1 in its digital transformation program powered by Salestack Solutions. This critical achievement marks the installation of the Salestack platform and provisioning of modern infrastructure—laying the foundation for accelerated innovation, operational efficiency, and long-term scalability. Mil
2025-08-21 8:00 AM EDT | iSpecimen Inc.
NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury
Vancouver, British Columbia--(Newsfile Corp. - August 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biopha
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-21 7:30 AM EDT | NervGen Pharma Corp.
Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights
Philadelphia, Pennsylvania--(Newsfile Corp. - August 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, is pleased to announce, following the acceptance of the Type C meeting request by the United States Food and Drug Administration (the "FDA"), the Company has submitted its queries in writing and expect to receive a response
Banking / Financial Services, Biotechnology, Investment Banking, Health
2025-08-21 7:30 AM EDT | Medicus Pharma Ltd.